Curis (FRA:CUS1) Cyclically Adjusted PS Ratio: (As of Jul. 16, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:CUS1 Curis Inc FRA:CUS1
55 GF Score
Price €4.20
GF Value €1.29
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Curis Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Curis  (FRA:CUS1) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Curis Cyclically Adjusted PS Ratio Related Terms


Curis Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Curis's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Curis Cyclically Adjusted PS Ratio Chart

Curis Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.46 0.06 0.10 0.03 0.01

Curis Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 0.02 0.02 0.01 0.00

FRA:CUS1 vs CALC, ICU, TRAW: Cyclically Adjusted PS Ratio Comparison

For the Biotechnology subindustry, Curis's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Curis Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Curis's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Curis's Cyclically Adjusted PS Ratio falls into.


FRA:CUS1
55GF Score
Curis Inc FRA:CUS1
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Curis Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Curis's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 is calculated as:

For example, Curis's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0/330.2130*330.2130
=0.000

Current CPI (Mar. 2026) = 330.2130.

Curis Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 23.000 241.018 31.512
201609 23.742 241.428 32.473
201612 31.986 241.432 43.748
201703 28.056 243.801 38.000
201706 25.472 244.955 34.338
201709 28.096 246.819 37.589
201712 33.610 246.524 45.020
201803 24.120 249.554 31.916
201806 24.313 251.989 31.860
201809 29.398 252.439 38.455
201812 29.181 251.233 38.355
201903 18.843 254.202 24.477
201906 22.325 256.143 28.781
201909 31.241 256.759 40.178
201912 35.639 256.974 45.796
202003 28.512 258.115 36.476
202006 21.172 257.797 27.119
202009 17.118 260.280 21.717
202012 15.067 260.474 19.101
202103 8.031 264.877 10.012
202106 8.284 271.696 10.068
202109 11.279 274.310 13.578
202112 12.114 278.802 14.348
202203 8.157 287.504 9.369
202206 9.886 296.311 11.017
202209 12.192 296.808 13.564
202212 11.307 296.797 12.580
202303 8.864 301.836 9.697
202306 8.380 305.109 9.069
202309 9.283 307.789 9.959
202312 8.554 306.746 9.208
202403 6.640 312.332 7.020
202406 8.127 314.175 8.542
202409 8.892 315.301 9.313
202412 8.318 315.605 8.703
202503 5.179 319.799 5.348
202506 3.777 322.561 3.867
202509 3.452 324.800 3.510
202512 1.232 324.054 1.255
202603 0.000 330.213 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Curis (FRA:CUS1) Overvalued in 2026?

Based on GuruFocus' analysis, Curis stock appears to be overvalued. The current stock price of €4.20 is trading 225.2% above its estimated GF Value™ of €1.29. GuruFocus considers Curis to be Significantly Overvalued.

Key valuation signals for FRA:CUS1:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: €1.29 vs. price of €4.20 (225.2% above fair value)
  • GF Score™: 55/100 with 5 warning signs

No single metric tells the full story. See the FRA:CUS1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Curis Business Description

Other Exchanges CRIS:USA
Address 128 Spring Street, Building C - Suite 500, Lexington, MA, USA, 02421
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
55GF Score

Get the complete analysis for FRA:CUS1

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.20
Price
€1.29
GF Value